Patents by Inventor Fuming QIU

Fuming QIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING BREAST AND OTHER CANCERS BY TARGETING ARGININOSUCCINATE SYNTHETASE 1-DEFICIENCY
    Publication number: 20220211824
    Abstract: Autophagy is the principal catabolic response to nutrient starvation. However, excessive autophagy can be cytotoxic or cytostatic, and contribute to cell death, but its mechanism of induction remains elusive. Here, it was demonstrated that prolonged arginine starvation by ADI-PEG20 induced an autophagy-dependent death of argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Consequently, arginine depleting agents such as ADI-PEG20 may be used in methods for killing one or more argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Further, abundance of ASS1 was either low or absent in more than 60% of 149 random breast cancer biosam pies, which could be exploited as candidates for arginine starvation therapy.
    Type: Application
    Filed: January 20, 2022
    Publication date: July 7, 2022
    Applicant: CITY OF HOPE
    Inventors: David K. ANN, Yun-Ru CHEN, Fuming QIU
  • Methods for treating breast and other cancers by targeting argininosuccinate synthetase 1-deficiency
    Patent number: 11311608
    Abstract: Autophagy is the principal catabolic response to nutrient starvation. However, excessive autophagy can be cytotoxic or cytostatic, and contribute to cell death, but its mechanism of induction remains elusive. Here, it was demonstrated that prolonged arginine starvation by ADI-PEG20 induced an autophagy-dependent death of argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Consequently, arginine depleting agents such as ADI-PEG20 may be used in methods for killing one or more argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Further, abundance of ASS1 was either low or absent in more than 60% of 149 random breast cancer biosamples, which could be exploited as candidates for arginine starvation therapy.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 26, 2022
    Assignee: CITY OF HOPE
    Inventors: David K. Ann, Yun-Ru Chen, Fuming Qiu
  • METHODS FOR TREATING BREAST AND OTHER CANCERS BY TARGETING ARGININOSUCCINATE SYNTHETASE 1-DEFICIENCY
    Publication number: 20160206712
    Abstract: Autophagy is the principal catabolic response to nutrient starvation. However, excessive autophagy can be cytotoxic or cytostatic, and contribute to cell death, but its mechanism of induction remains elusive. Here, it was demonstrated that prolonged arginine starvation by ADI-PEG20 induced an autophagy-dependent death of argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Consequently, arginine depleting agents such as ADI-PEG20 may be used in methods for killing one or more argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Further, abundance of ASS1 was either low or absent in more than 60% of 149 random breast cancer biosamples, which could be exploited as candidates for arginine starvation therapy.
    Type: Application
    Filed: April 1, 2016
    Publication date: July 21, 2016
    Inventors: David K. ANN, Yun-Ru CHEN, Fuming QIU, Hsing-Jien KUNG